Alendronate sodium and vitamin D in postmenopausal osteoporosis

A systematic review

Authors

DOI:

https://doi.org/10.15448/1980-6108.2022.1.42267

Keywords:

osteoporosis, postmenopause, alendronate, vitamin D, bone recovery

Abstract

Aim: to evaluate the effectiveness of using the combined therapy of sodium alendronate and vitamin D on bone metabolism in women undergoing postmenopausal osteoporosis. 
Methods: this is a systematic review. The studies included were Randomized Controlled Trials (RCT) indexed in the BVS, ISI Web of Science, PubMed, SciELO, ScienceDirect and Scopus Databases which compared the association of sodium alendronate and vitamin D to monotherapy of sodium alendronate. 
Results: a total of six RCT met the criteria to be included in this study, comprising a total of 4164 participants and their respective data. The studies evaluated different domains of bone metabolism, such as serum levels of vitamin D, parathyroid hormone, bone mineral density and bone turnover markers. Combination therapy produced significant improvement in bone metabolic markers. 
Conclusion: combined therapy of sodium alendronate with vitamin D promotes improved bone metabolism in women with postmenopausal osteoporosis.

Downloads

Download data is not yet available.

Author Biographies

José Reginaldo Alves de Queiroz Júnior, Universidade Federal de Pernambuco (UFPE), Centro de Ciências Médicas, Recife, PE, Brasil.

Graduando em Medicina pela Universidade Federal de Pernambuco (UFPE), em Recife, PE, Brasil.

Jarson Pedro da Costa Pereira, Universidade Federal de Pernambuco (UFPE), Hospital das Clínicas, Recife, PE, Brasil.

Mestrando em Nutrição e Saúde Pública pela Universidade Federal de Pernambuco (UFPE), em Recife, PE, Brasil.

Leonardo Lucas Pires, Universidade Potiguar (UnP), Departamento de Ciências Médicas, Natal, RN, Brasil.

Graduando em Medicina pela Universidade Potiguar (UnP), em Natal, RN, Brasil. 

Carina Scanoni Maia, Universidade Federal de Pernambuco (UFPE), Departamento de Histologia e Embriologia, Recife, PE, Brasil.

Doutora em Biociência Animal pela Universidade Federal Rural de Pernambuco (UFRPE), em Recife, PE, Brasil; Professora da Universidade Federal de Pernambuco (UFPE), em Recife, PE, Brasil.

References

Radominski SC, Bernardo W, Paula AP, Albergaria B, Moreira C, Fernandes CE, et al. Diretrizes brasileiras para o diagnóstico e tratamento da osteoporose em mulheres na pós-‐menopausa. Rev Bras Reumatol. 2017;57:452-66. https://doi.org/10.1016/j.rbre.2017.07.001

Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatmentof osteoporosis. Osteoporos Int. 2014;25:2359. https://doi.org/10.1007/s00198-014-2794-2

NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001; 285:785-95. https://doi.org/10.1001/jama.285.6.785

Lazaretti-Castro M, Eis SR, Marques Neto JF. A prevenção da osteoporose levada a sério: uma necessidade nacional. Arq Bras Endrocrinol Metab. 2008;52(4):712-3. https://doi.org/10.1590/S0004-27302008000400020

Mabey T, Honsawek S. Role of Vitamin D in osteoarthritis: molecular, cellular, and clinical perspectives. Int J Endocrinol. 2015;2015:1-14. https://doi.org/10.1155/2015/383918

Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-81. https://doi.org/10.1056/NEJMra070553

Narula K, Tauseef M, Ahmad I, Agarwal K, Ashok A, Anjana A. Vitamin D deficiency among postmenopausal women with osteoporosis. J Clin Diagn Res. 2013;7:336-8. https://doi.org/10.7860/JCDR/2013/5022.2761

Sahota O. Osteoporosis and the role of vitamin D and calcium-vitamin D deficiency, vitamin D insufficiency and vitamin D sufficiency. Age Ageing. 2000;29:301-4. https://doi.org/10.1093/ageing/29.4.301

Rosen CJ. The Epidemiology and pathogenesis of osteoporosis [Updated 2014 Jan 10]. In: De Groot LJ, Chrousos G, Dungan K, et al., editors. Endotext South Dartmouth (MA): MDText com, Inc. 2014; 2000: Available from: https://www.ncbi.nlm.nih.gov/books/NBK279134.

Agnusdei D, Crepaldi G, Isaia G, et al. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss. Calcif Tissue Int. 1997;61(2):142-147. https://doi.org/10.1007/s002239900312

Kocijan R, Klaushofer K, Misof BM. Osteoporosis therapeutics 2020, Berlin, Heidelberg: Springer Berlin Heidelberg; 2020.

Shane E. Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med. 2010;362(19):1761-71. https://doi.org/10.1056/NEJMe1003064

Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone. 2007;40(5): 1238-43. https://doi.org/10.1016/j.bone.2007.01.016

Higgins JP, Thomas J, Chandler J et al., editors. Cochrane handbook for systematic reviews of interventions. Chichester (UK): John Wiley & Sons; 2019.

Roux C, Binkley N, Boonen S, et al. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis. Calcif Tissue Int. 2014;94(2):153-7. https://doi.org/10.1007/s00223-013-9763-1

Kim KJ, Min YK, Koh JM, et al. Efficacy and safety of weekly alendronate plus vitamin D₃ 5600 IU versus weekly alendronate alone in korean osteoporotic women: 16-week randomized trial. Yonsei Med J. 2014;55(3):715-24. https://doi.org/10.3349/ymj.2014.55.3.715

Olmos JM, Hernández JL, Llorca J, et al. Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate. J Clin Endocrinol Metab. 2012;97(12):4491–7. https://doi.org/10.1210/jc.2012-2999

Orimo H, Nakamura T, Fukunaga M, et al. Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the japanese osteoporosis intervention trial (JOINT) - 02. Curr Med Res Opin. 2011;27(6):1273-84. https://doi.org/10.1185/03007995.2011.580341

Binkley N, Ringe JD, Reed JI, Ljunggren O, Holick MF, Minne HW, Liu M, Lamotta A, West JA, Santora AC. Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trial. Bone. 2009;44(4):639-47. https://doi.org/10.1016/j.bone.2008.05.002

Recker R, Lips P, Felsenberg D, et al. Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial. Curr Med Res Opin. 2006;22(9):1745-55. https://doi.org/10.1185/030079906x120913

Mata PR, Martins PA, Brito LG, Ramos MMP, Santos Junior, MC. Tratamento farmacológico para a osteoporose. Geriatrics, Gerontology and Aging. 2012;6(4):422–31.

Benjamin B, Benjamin MA, Swe M, Sugathan S. Review on the comparison of effectiveness between denosumab and bisphosphonates in post-menopausal osteoporosis. Osteoporosis and Sarcopenia. 2016;2:77-81. https://doi.org/10.1016/j.afos.2016.03.003

Drieling RL, LaCroix AZ, Beresford SAA, Boudreau DM, Kooperberg C, Chlebowski RT, et al. Long-Term oral bisphosphonate therapy and fractures in older women: the women’s health initiative. J Am Geriatr Soc. 2017;65:1924-31. https://doi.org/10.1111/jgs.14911

Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. JMCP. 2009;15:728-40. https://doi.org/10.18553/jmcp.2009.15.9.728

Barrett-Connor E, Wade SW, Do TP, Satram-Hoang S, Stewart R, Gao G, et al. Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE USTM. Osteoporos Int. 2012;23:733-41. https://doi.org/10.1007/s00198-011-1620-3

Leib ES, Lewiecki EM, Binkley N, Hamdy RC. Official positions of the international society for clinical densitometry. J Clin Densitom. 2004;7:1-6. https://doi.org/10.1385/JCD:7:1:1

Eastell R, Szulc P. Use of bone turnover markers in postmenopausal osteoporosis. The Lancet Diabetes & Endocrinology. 2017;5:908-23. https://doi.org/10.1016/S2213-8587(17)30184-5

Vasikaran SD. Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem. 2001;38(6):608-623. https://doi.org/10.1258/0004563011901037

Horwitz MJ, Tedesco MB, Sereika SM, Syed MA, Garcia-Ocaña A, Bisello A, et al. Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D. J Bone Miner Res. 2005;20:1792-1803. https://doi.org/10.1359/JBMR.050602

Cândido F, Bressan J. Vitamin D: Link between Osteoporosis, obesity, and diabetes? IJMS. 2014;15:6569-91. https://doi.org/0.3390/ijms15046569

Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005;293:2257. https://doi.org/10.1001/jama.293.18.2257

Downloads

Published

2022-08-25

How to Cite

Júnior, J. R. A. de Q., Pereira, J. P. da C., Pires, L. L., & Maia, C. S. (2022). Alendronate sodium and vitamin D in postmenopausal osteoporosis: A systematic review. Scientia Medica, 32(1), e42267. https://doi.org/10.15448/1980-6108.2022.1.42267

Issue

Vol. 32 No. 1 (2022): Single Volume

Section

Systematic Review and Meta-Analysis

License

Copyright (c) 2022 Scientia Medica

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright

The submission of originals to Scientia Medica implies the transfer by the authors of the right for publication. Authors retain copyright and grant the journal right of first publication. If the authors wish to include the same data into another publication, they must cite Scientia Medica as the site of original publication.

Creative Commons License

Except where otherwise specified, material published in this journal is licensed under a Creative Commons Attribution 4.0 International license, which allows unrestricted use, distribution and reproduction in any medium, provided the original publication is correctly cited.